Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Bull Exp Biol Med ; 171(4): 480-482, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34542754

RESUMEN

We studied the effect of nitinol, the most prevalent material for endovascular stents, on metabolic and coagulation activity of a primary culture of human umbilical vein endothelial cells (HUVEC). Metabolic activity was evaluated using MTS-test and by the level of stable NO metabolites in the conditioned medium, coagulation activity was assessed by activity of von Willebrand factor (vWF) and levels of plasminogen activator inhibitor-1 (PAI-1) and soluble endothelial protein C receptors (sEPCR). Exposure to nitinol reduced metabolic activity of the cell culture by 11.1% in comparison with the control (p<0.001). Although absolute activity of vWF and absolute level of sEPCR were elevated, incubation with nitinol did not lead to a statistically significant elevation of these parameters in comparison with the control, which can indicate the absence of substantial hypercoagulation effects of nitinol.


Asunto(s)
Aleaciones/farmacología , Endotelio Vascular/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Coagulación Sanguínea/efectos de los fármacos , Factores de Coagulación Sanguínea/metabolismo , Células Cultivadas , Receptor de Proteína C Endotelial/efectos de los fármacos , Receptor de Proteína C Endotelial/metabolismo , Endotelio Vascular/metabolismo , Endotelio Vascular/fisiología , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Células Endoteliales de la Vena Umbilical Humana/fisiología , Humanos , Inhibidor 1 de Activador Plasminogénico/efectos de los fármacos , Inhibidor 1 de Activador Plasminogénico/metabolismo , Trombosis/metabolismo , Trombosis/patología , Factor de von Willebrand/efectos de los fármacos , Factor de von Willebrand/metabolismo
2.
Angiol Sosud Khir ; 23(4): 69-74, 2017.
Artículo en Ruso | MEDLINE | ID: mdl-29240058

RESUMEN

The problem of venous thromboembolic complications (VTECs) in patients with cardiovascular implantable electronic devices (CIEDs) is extremely important today because of an annually increasing number of surgical interventions for life-threatening arrhythmias and chronic heart failure. There are hitherto no clearly defined reliable risk factors for VTECs due to heterogeneity of the available literature data. Some sources point to elevated thrombus formation in patients with a large number of electrodes, in repeat operative interventions, in the presence of a temporary pacemaker, in implantation on the left side, silicon cover of an electrode, others refute these facts. Still undetermined remains the choice of antithrombotic therapy for prevention and treatment of VTECs in this cohort of patients. Implantation of a VTEC may be accompanied by thrombosis of deep veins of the upper extremities up to the development of total occlusion of veins. In rare cases, thrombosis extends proximally, there appears superior vena cava syndrome which may require surgical treatment. Diagnosis of these diseases is complicated by their symptom-free course in the majority of cases. The most dangerous VTEC is pulmonary thromboembolism very commonly not accompanied by clinical symptomatology or taking its course under the mask of other more frequent diseases. Despite the fact that pulmonary thromboembolism with a source in the system of the superior vena cava is rarely massive, it may lead to the development of chronic postembolic pulmonary hypertension and to decreased quality of life. The article contains a review of the present-day literature and a clinical case report concerning the development of VTECs in a patient with a CIED in the form of thrombosis of the right internal jugular, subclavian and brachiocephalic veins, pulmonary embolism of small branches of the right pulmonary artery, suppuration of the pacemaker's bed and sepsis. Therapy with antibiotics, low-molecular-weight heparins, antiplatelet drugs and anti-inflammatory agents with regular sanitation of the pacemaker's bed turned out effective.


Asunto(s)
Antibacterianos/administración & dosificación , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Heparina de Bajo-Peso-Molecular/administración & dosificación , Venas Yugulares , Marcapaso Artificial , Implantación de Prótesis , Rivaroxabán/administración & dosificación , Vena Subclavia , Infección de la Herida Quirúrgica , Tromboembolia , Anciano , Anticoagulantes/administración & dosificación , Bloqueo Atrioventricular/cirugía , Procedimientos Quirúrgicos Cardíacos/métodos , Humanos , Venas Yugulares/diagnóstico por imagen , Venas Yugulares/patología , Masculino , Implantación de Prótesis/efectos adversos , Implantación de Prótesis/métodos , Ajuste de Riesgo , Vena Subclavia/diagnóstico por imagen , Vena Subclavia/patología , Vena Subclavia/cirugía , Infección de la Herida Quirúrgica/diagnóstico , Infección de la Herida Quirúrgica/tratamiento farmacológico , Infección de la Herida Quirúrgica/fisiopatología , Tromboembolia/diagnóstico , Tromboembolia/tratamiento farmacológico , Tromboembolia/etiología , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento , Ultrasonografía Doppler Dúplex/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA